2C-EF

2C-EF is a psychedelic drug and phenethylamine of the 2C family. It was first synthesized by Alexander Shulgin.

History

2C-EF was first synthesized and documented by Alexander Shulgin. In his book PiHKAL, Shulgin lists the dosage as 10-25 mg and the duration as 8-12 hours. He describes 2C-EF as a psychedelic phenethylamine with effects that are similar to, but not identical to, those of other 2C drugs.

Chemistry

2C-EF is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. It is structurally similar to other drugs in the 2C family, such as 2C-E and 2C-I, which are also substituted phenethylamines. However, 2C-EF has an additional fluoro atom attached to the ethyl chain, which distinguishes it from other 2C drugs.

Pharmacology

Like other 2C drugs, 2C-EF is believed to act primarily as a 5-HT2A receptor agonist. The 5-HT2A receptor is a subtype of the 5-HT2 receptor that resides within the serotonin system. When 2C-EF binds to these receptors, it leads to the release of serotonin, a neurotransmitter that is involved in regulating mood, appetite, sleep, and other functions.

Effects

The effects of 2C-EF can vary greatly depending on the dose and individual's physiology. Some users report experiencing visual hallucinations, altered thinking processes, and heightened emotions. Other effects can include feelings of euphoria, increased empathy, and changes in perception of time. However, like all psychedelic drugs, 2C-EF can also cause negative effects such as anxiety, paranoia, and uncomfortable physical sensations.

Legal Status

The legal status of 2C-EF varies by country. In the United States, it is not specifically listed as a controlled substance, but it could potentially be considered an analog of 2C-E or 2C-I, which are both Schedule I drugs.

See Also

• 2C-B
• 2C-I
• 2C-E
• Phenethylamine
• Psychedelic drug

2C-EF Resources
Latest articles Most recent articles Ongoing trials	Wikipedia